Harnessing In Vivo Disease Models to Turbocharge Treatment Success
Time: 4:30 pm
day: Conference Day One PM
Details:
- Exploring CAR/TCR/alarmin mediated in vivo targeting for autoimmune and inflammatory diseases
- Illuminating context specific Treg functions including controlling B-cell mediated autoimmunity, tissue repair and tissue protection
- Optimizing murine models to uncover the mechanism of action for Treg cell therapy in autoimmune and inflammatory diseases
- Prioritizing translational relevance of key preclinical biomarkers and endpoints to inform on likelihood of efficacy
